Fighting neurodegeneration with rapamycin: mechanistic insights.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21772323.
- Also identified by DOI 10.1038/nrn3068.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A growing number of studies point to rapamycin as a pharmacological compound that is able to provide neuroprotection in several experimental models of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease and spinocerebellar ataxia type 3. In addition, rapamycin exerts strong anti-ageing effects in several species, including mammals. By inhibiting the activity of mammalian target of rapamycin (mTOR), rapamycin influences a variety of essential cellular processes, such as cell growth and proliferation, protein synthesis and autophagy. Here, we review the molecular mechanisms underlying the neuroprotective effects of rapamycin and discuss the therapeutic potential of this compound for neurodegenerative diseases.
Medical subject headings
- Nerve Degeneration
- Neurodegenerative Diseases
- Sirolimus
- TOR Serine-Threonine Kinases